Snoopy-Typing-Away-1-CVV14J0D95-1024x768

NEW YORK (TheStreet) — Codexis (CDXS_) soared to a 52-week high of $2.65 on Tuesday after the biocatalyst developer announced a technology licensing agreement with GlaxoSmithKline (GSK_).

The deal grants GlaxoSmithKline a license to use Codexis’ CodeEvolver protein engineering platform technology to develop enzymes to help manufacture its pharmaceutical and health care products. GSK can also use it to create new therapeutic, diagnostic and prophylactic products.

Codexis can receive up to $25 million in approximately the next two years, $6 million up front and the other $19 million “subject to satisfactory completion of technology transfer milestones,” according to the agreement. Codexis can also receive additional milestone payments of $5.75 million to $38.5 million per project “based on GSK’s successful application of the licensed technology.” Finally, Codexis is eligible for royalties from net sales of some GSK products developed with CodeEvolver.

My perennial underperformer might just catch fire.

Advertisements